AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 15, 2025, discloses a material definitive agreement entered into by AEON Biopharma, Inc. (the "Company") and its subsidiary, AEON Biopharma Sub, Inc., with Daewoong Pharmaceuticals, Co., LTD ("Daewoong"). The filing details an Exchange Agreement to restructure existing senior secured convertible notes held by Daewoong.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The financial significance of this filing is derived from the restructuring of debt and equity instruments:
- Existing Debt: Up to $15,000,000 in principal amount of senior secured convertible notes issued in March 2024.
- New Debt Instrument: A new senior secured convertible note ("New Convertible Note") with a principal amount of $1,500,000.
- Interest Rate: The New Convertible Note accrues interest at an annual rate of 15.79%, payable in cash at maturity.
- Maturity Date: April 12, 2030.
- Equity Issuance: Approximately 23.1 million shares of Class A Common Stock (or Pre-Funded Warrants) to be issued to Daewoong, subject to beneficial ownership limitations (49.99%).
- Warrants: Issuance of warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share.
Material Changes and Transaction Mechanics
The Exchange Agreement replaces the existing Convertible Notes with a mix of equity, a smaller new debt instrument, and warrants. Key mechanics include:
- Conversion Formula: The number of Exchange Shares is calculated based on the principal and accrued interest of the old notes, less the $1.5 million new note principal, divided by $1.00, and multiplied by a 1.3x factor.
- Security Interest: The Company and its subsidiary will grant a first-priority security interest on substantially all assets to secure the New Convertible Note.
- Board Representation: Daewoong will nominate one designee (currently Seongsoo Park) to the Company's board of directors as a Class III director.
- Restrictions: The New Convertible Note restricts the issuance of senior or pari passu debt without Daewoong's consent and limits junior debt issuance.
Guidance, Outlook, Risks, and Contingencies
Conditions Precedent: The transaction is contingent upon stockholder approval in accordance with NYSE American rules and other customary closing conditions. The Company estimates the stockholder vote will occur on January 21, 2026.
Conversion Triggers:
- Qualified Financing: If the Company raises at least $30.0 million in a bona-fide third-party financing, the New Convertible Note will automatically convert into equity at a 1.3x multiple of the financing price.
- Optional Conversion: Daewoong has the right to convert the note upon the submission of a Biologics License Application (BLA) for ABP-450 or a Change of Control, using a 1.3x multiple of the 5-day VWAP.
Risks: The filing highlights risks regarding the failure to obtain stockholder approval, failure to satisfy closing conditions, and the dilutive impact of the equity issuance. The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the outcome of the stockholder vote scheduled for January 21, 2026, to confirm if the Exchange will close.
- Review the full text of the Exchange Agreement (Exhibit 10.1) and New Convertible Note (Exhibit 4.1) for specific covenants and default provisions.
- Monitor the Company's cash position and ability to service the 15.79% interest on the new note until maturity or conversion.
- Assess the dilution impact of the estimated 23.1 million Exchange Shares and 8 million warrant shares on existing shareholders.
- Track the development status of ABP-450, as a BLA submission triggers an optional conversion right for Daewoong.